Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Liabilities and Shareholders Equity (2018 - 2025)

Exagen (XGN) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $58.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 29.84% year-over-year to $58.0 million, compared with a TTM value of $219.9 million through Dec 2025, up 16.71%, and an annual FY2025 reading of $58.0 million, up 29.84% over the prior year.
  • Liabilities and Shareholders Equity was $58.0 million for Q4 2025 at Exagen, down from $62.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $137.5 million in Q1 2021 and bottomed at $40.3 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $80.4 million, with a median of $63.5 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 65.59% in 2021, then tumbled 40.03% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $123.4 million in 2021, then plummeted by 30.15% to $86.2 million in 2022, then tumbled by 33.96% to $56.9 million in 2023, then fell by 21.52% to $44.7 million in 2024, then grew by 29.84% to $58.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for XGN at $58.0 million in Q4 2025, $62.8 million in Q3 2025, and $58.8 million in Q2 2025.